RecruitingNot ApplicableNCT07114718
Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study
Sponsor
Starlight Cardiovascular Inc
Enrollment
35 participants
Start Date
Jan 16, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
Starlight Cardiovascular, Inc. is sponsoring a prospective, multi-center, study to evaluate safety and effectiveness of the Lifeline Ductus Arteriosus Stent System. The study device is a stent that is designed to maintain patency of the Ductus Arteriosus for children who need blood flow through that part of the heart.
Eligibility
Min Age: 1 MinuteMax Age: 6 Months
Inclusion Criteria4
- Parental or legal authorized representative provide consent for study enrollment
- Infants < 6 months of age
- Diagnosis of congenital heart defect with ductal-dependent pulmonary circulation requiring infusion of prostaglandins
- Requires ductus arteriosus stent diameters of 3.5mm or 4mm and stent lengths between 16mm and 28mm
Exclusion Criteria20
- Active blood stream infection
- Active or history of endocarditis
- Body weight <2.5kg
- Gestational age <32 weeks at birth
- Complete heart block
- Total Anomalous Pulmonary Venous Return
- Anatomic variation judged to be inappropriate for ductal stenting per the treating interventionalist
- Presence of an aortopulmonary collateral that is expected to require unifocalization
- Non-confluent pulmonary arteries (i.e. isolated pulmonary artery of ductal origin) or bilateral patent ductus arteriosus (PDA)
- Pulmonary atresia with intact ventricular septum with RV-dependent coronary circulation
- Currently participating in an investigational drug study or another device study that would confound the study results
- Patient who is on extracorporeal membrane oxygenation (ECMO), ventricular assist device (VAD), or dialysis prior to ductal stenting procedure
- Major co-morbidities which, in the opinion of the investigator, would negatively alter expected 1-year survival (e.g., intracranial hemorrhage, renal failure, etc.)
- Patient who is undergoing another transcatheter procedure (e.g., atrial septostomy, aortic arch intervention, or right ventricular outflow tract intervention) during or within 24 hours prior to the ductus arteriosus stenting procedure
- Patient who, at the time of enrollment, is deemed not to be a candidate for eventual stage II palliation of single ventricle heart disease, complete surgical repair, nor transcatheter treatment with resultant biventricular circulation
- Patient who does not plan to return to the enrolling center or another participating center for stage II palliation, complete surgical repair, or definitive catheterization procedure
- Contraindications to peri-procedural anticoagulation
- Known to be non-responsive to aspirin or other antiplatelet therapies
- Known hypersensitivity or allergy to Nickel
- Known hypersensitivity to contrast media that cannot be adequately pre-medicated
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICEDuctus Arteriosus Stent
The eligible subjects will proceed to implantation of the Lifeline Ductus Arteriosus Stent to maintain patency of the PDA.
Locations(8)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07114718
Related Trials
PDA for Kidneys Study
NCT066584961 location
Effectiveness of High-Energy Density Enteral Nutrition for Enhancing Physical Growth and Cognitive Brain Development in Infants With Congenital Heart Disease
NCT071151081 location
Prenatal Maternal Mental Health and Neurodevelopment in Congenital Heart Disease
NCT067116665 locations
Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment
NCT052135981 location
Transition and Transfer of Congenital Heart Disease Care From Pediatrics to Adulthood
NCT075851751 location